MX2020011955A - Derivados heterociclicos y uso de los mismos. - Google Patents

Derivados heterociclicos y uso de los mismos.

Info

Publication number
MX2020011955A
MX2020011955A MX2020011955A MX2020011955A MX2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A MX 2020011955 A MX2020011955 A MX 2020011955A
Authority
MX
Mexico
Prior art keywords
pain
disease
nasal
inflammatory
treatment
Prior art date
Application number
MX2020011955A
Other languages
English (en)
Inventor
Jung Sook Kim
Soon Ok Lee
Kwang Seok Ko
Ji Eun Lee
Jee Hun Yun
Young Jin Kwon
Nam Chul Cho
Original Assignee
C&C Res Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&C Res Lab filed Critical C&C Res Lab
Publication of MX2020011955A publication Critical patent/MX2020011955A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona a compuestos heterocíclicos novedosos útiles en la preparación de fármacos para el tratamiento de enfermedades asociadas con varias funciones del receptor de histamina 4. Específicamente, estos fármacos son útiles en la prevención o tratamiento de trastorno inflamatorio, alergia, dolor, pólipos nasales, rinitis, sinusitis crónica, congestión nasal, picazón nasal, asma, enfermedad pulmonar obstructiva crónica, artritis reumatoide, dermatitis atópica, psoriasis, eczema, prurito, picazón de la piel, urticaria, urticaria crónica idiopática, escleroderma, conjuntivitis, ceratoconjuntivitis, inflamación ocular, ojo seco, degeneración macular relacionada a la edad, disfunción cardiaca, arritmia, aterosclerosis, esclerosis múltiple, enfermedad inflamatoria de intestino (colitis, enfermedad de Crohn, colitis ulcerativa), dolor inflamatorio, dolor neuropático, dolor osteoartrítico, enfermedad de tiroides autoinmune, diabetes inmuno-mediada (también conocida como tipo I), lupus, adhesiones post-operativas, trastornos vestibulares y cáncer.
MX2020011955A 2018-05-31 2019-05-31 Derivados heterociclicos y uso de los mismos. MX2020011955A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180062254 2018-05-31
PCT/KR2019/006553 WO2019231270A1 (en) 2018-05-31 2019-05-31 Heterocyclic derivatives and use thereof

Publications (1)

Publication Number Publication Date
MX2020011955A true MX2020011955A (es) 2021-01-15

Family

ID=68698381

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011955A MX2020011955A (es) 2018-05-31 2019-05-31 Derivados heterociclicos y uso de los mismos.

Country Status (12)

Country Link
US (1) US20210198259A1 (es)
EP (1) EP3807282A4 (es)
JP (1) JP2021525738A (es)
KR (1) KR102344295B1 (es)
CN (1) CN112204032A (es)
AU (1) AU2019279421A1 (es)
BR (1) BR112020023946A2 (es)
CA (1) CA3098825A1 (es)
MX (1) MX2020011955A (es)
SG (1) SG11202010985TA (es)
TW (1) TW202021969A (es)
WO (1) WO2019231270A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
IL298760A (en) 2020-06-05 2023-02-01 Kinnate Biopharma Inc Fibroblast growth factor receptor kinase inhibitors
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
CN113929634A (zh) * 2021-11-22 2022-01-14 山西永津集团有限公司 一种2,3-二溴喹喔啉的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE358395B (es) * 1967-09-27 1973-07-30 Siegfried Ag
MXPA05010293A (es) * 2003-03-27 2005-11-17 Pfizer Prod Inc 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
UY32111A (es) * 2008-09-10 2010-04-30 Alcon Res Ltd Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
TW201206936A (en) * 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
RU2628074C2 (ru) * 2011-09-30 2017-08-14 Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ ТРИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-с]ПИРИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕЦЕПТОРА ГИСТАМИНА 4 (hH4R)
EP2968311A4 (en) * 2013-03-15 2016-07-20 Epigenetix Inc OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS
EP3377490A1 (en) * 2015-11-16 2018-09-26 Fundacion para la Investigacion Medica Aplicada Novel compounds as inhibitors of dna methyltransferases
WO2018022865A1 (en) * 2016-07-28 2018-02-01 Promega Corporation Coelenterazine analogues

Also Published As

Publication number Publication date
JP2021525738A (ja) 2021-09-27
TW202021969A (zh) 2020-06-16
WO2019231270A1 (en) 2019-12-05
KR102344295B1 (ko) 2021-12-29
BR112020023946A2 (pt) 2021-02-23
EP3807282A1 (en) 2021-04-21
US20210198259A1 (en) 2021-07-01
CN112204032A (zh) 2021-01-08
EP3807282A4 (en) 2022-03-02
CA3098825A1 (en) 2019-12-05
AU2019279421A1 (en) 2020-12-03
SG11202010985TA (en) 2020-12-30
KR20190137013A (ko) 2019-12-10

Similar Documents

Publication Publication Date Title
MX2014003042A (es) Nuevos derivados heterociclicos y sus usos.
MX2020011955A (es) Derivados heterociclicos y uso de los mismos.
SA519402319B1 (ar) Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
BRPI0314830B8 (pt) derivados de azol-pirimidina fundida
MX2008011369A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2.
MY145648A (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
TW200639151A (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
SG155909A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
PH12018500940A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
TNSN07098A1 (en) 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
JOP20170136B1 (ar) ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية
CY1112805T1 (el) Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης
RU2018142605A (ru) Селективный ингибитор фосфатидилинозитол-3-киназы-гамма
EA201190302A1 (ru) ПРОИЗВОДНЫЕ 7-АРИЛ-1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
WO2015139051A3 (en) Nanocarriers and their processing for diagnostics and therapeutics
JP2016531861A5 (es)
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MX2021000270A (es) Derivados de la tirosina amida como inhibidores de la rho- cinasa.
MX2021000759A (es) Derivados de triazolquinoxalina adicionalmente sustituidos.
MX2017008382A (es) Formas cristalinas de apomorfina y sus usos.
NZ592919A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
MX2017007663A (es) Moleculas tipo inmunoglobulina dirigidas contra fibronectina eda.
Wang et al. Molecular mechanism of idiopathic basal ganglia calcification